Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2017

01-07-2017 | Special Feature

Post-mastectomy radiation therapy in breast cancer with 1–3 involved lymph nodes: the Pros

Authors: Keiichiro Tada, Kotoe Nishioka, Yasuko Kikuchi, Takayoshi Niwa, Yasuyuki Seto

Published in: Breast Cancer | Issue 4/2017

Login to get access

Abstract

In 2014, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported that post-mastectomy radiation therapy (PMRT) for breast cancer patients with 1–3 cancer-positive lymph nodes is associated with a survival benefit. However, it is not known whether this applies to Japanese patients in daily clinical practice, because this conclusion was based on the results of older, western trials. Therefore, we studied the differences between PMRT results in western breast cancer patients and current practice in Japanese patients. Although we identified three differences, they do not appear to strongly impact the results of EBCTCG. We conclude that Japanese breast cancer patients with 1–3 positive lymph nodes should receive PMRT in daily clinical practice.
Literature
1.
Early Breast Cancer Trialists’ Collaborative Group, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–44.CrossRef
2.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRefPubMed
3.
Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:989–90.CrossRefPubMed
4.
Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.CrossRefPubMed
5.
Early Breast Cancer Trialists’ Collaborative Group, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127–35.CrossRef
6.
Matsunuma R, Oguchi M, Fujikane T, Matsuura M, Sakai T, Kimura K, et al. Influence of lymphatic invasion on locoregional recurrence following mastectomy: indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. Int J Radiat Oncol Biol Phys. 2012;83:845–52.CrossRefPubMed
7.
Hamamoto Y, Ohsumi S, Aogi K, Shinohara S, Nakajima N, Kataoka M, et al. Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy? Breast Cancer. 2014;21:177–82.CrossRefPubMed
8.
Nagao T, Kinoshita T, Tamura N, Hojo T, Morota M, Kagami Y. Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy. Int J Clin Oncol. 2013;18:54–61.CrossRefPubMed
9.
Ofuchi T, Amemiya A, Takeda A. The efficacy of postmastectomy radiotherapy in patients with breast cancer. Jpn J Breast Cancer. 2006;21:443–9.
10.
Maaskant AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Tutein Nolthenius-Puylaert MC, Nieuwenhuijzen GA. Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res Treat. 2009;113:173–9.CrossRefPubMed
11.
Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21:355–60.CrossRefPubMed
12.
Marchal C, Weber B, de Lafontan B, Resbeut M, Mignotte H, du Chatelard PP, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys. 1999;44:113–9.CrossRefPubMed
13.
West JG, Qureshi A, West JE, Chacon M, Sutherland ML, Haghighi B, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J. 2005;11:115–23.CrossRefPubMed
14.
Taylor CW, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003–2013. Int J Radiat Oncol Biol Phys. 2015;93:845–53.CrossRefPubMed
15.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.CrossRefPubMedPubMedCentral
16.
Coen JJ, Taghian AG, Kachnic LA, Assaad SI, Powell SN. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1209–15.CrossRefPubMed
17.
Torres Lacomba M, Yuste Sanchez MJ, Zapico Goni A, Prieto Merino D, Mayoral del Moral O, Cerezo Tellez E, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010;340:b5396.CrossRefPubMedPubMedCentral
18.
Tada K. Recommendation for post-mastectomy radiation therapy for breast cancer patients with one to three positive lymph nodes; a) Approval for this idea. Rinsyo Zasshi Geka. 2017;79:402–4.
Metadata
Title
Post-mastectomy radiation therapy in breast cancer with 1–3 involved lymph nodes: the Pros
Authors
Keiichiro Tada
Kotoe Nishioka
Yasuko Kikuchi
Takayoshi Niwa
Yasuyuki Seto
Publication date
01-07-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0787-7

Other articles of this Issue 4/2017

Breast Cancer 4/2017 Go to the issue

Original Article

Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study

Erratum

Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Special Feature

Breast reconstruction and postmastectomy radiotherapy: complications by type and timing and other problems in radiation oncology

Special Feature

Controversies in the role of postmastectomy radiotherapy in breast cancer patients with one to three positive axillary nodes and safety of integrating radiotherapy and breast reconstruction

Original Article

NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer

Special Feature

Postmastectomy radiation therapy and breast reconstruction with autologous tissue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits